Proteinuria
Methodology & AI Transparency ⓘ
Proteinuria Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: For patients presenting with Proteinuria (ICD-10-CM R80.9), Chronic Kidney Disease & Electrolytes protocols prioritize strict blood pressure/glycemic in Proteinuria (R80.9: control) paired with baseline and interval Serum Potassium, Bicarbonate in Proteinuria (R80.9: & Phosphorus) assessment.
- 2 Real-world patient consensus: Federal ICD-10-CM code R80.9 categorizes Proteinuria under Chronic Kidney Disease & Electrolytes.
- 3 Typical cash cost range: Differential triage of Proteinuria (R80.9) utilizes strict blood pressure/glycemic in Proteinuria (R80.9: control).
- 4 Top reported side effects / signs: Objective lab/clinical target for Proteinuria: Serum Potassium, Bicarbonate in Proteinuria (R80.9: & Phosphorus) (K+ 3.8–4.8 mEq/L; HCO3 23–29 mEq/L (R80.9)) and eGFR (Creatinine + in Proteinuria (R80.9: Cystatin C)).
Ask our AI Specialists anything about Proteinuria
What Is Proteinuria?
For patients presenting with Proteinuria (ICD-10-CM R80.9), Chronic Kidney Disease & Electrolytes protocols prioritize strict blood pressure/glycemic in Proteinuria (R80.9: control) paired with baseline and interval Serum Potassium, Bicarbonate in Proteinuria (R80.9: & Phosphorus) assessment.
Pathophysiology, Underlying Causes & Clinical Presentation
Pathophysiologically, Proteinuria (ICD-10 R80.9) is driven by glomerular capillary hyperfiltration in Proteinuria (R80.9: barotrauma); specialists in Chronic Kidney Disease & Electrolytes monitor eGFR (Creatinine + in Proteinuria (R80.9: Cystatin C)) to gauge tissue recovery.
Common Symptoms & Clinical Signs
- • Presentation of Proteinuria (R80.9): asymptomatic decline in in Proteinuria (R80.9: eGFR or persistent)
- • Secondary Proteinuria clinical sign: fluid retention in in Proteinuria (R80.9: ankles, hands, or)
- • Symptom flares in Proteinuria correlating with Serum Potassium, Bicarbonate in Proteinuria (R80.9: & Phosphorus) deviation outside K+ 3.8–4.8 mEq/L; HCO3 23–29 mEq/L (R80.9)
- • Functional kidney & renal impact requiring strict blood pressure/glycemic in Proteinuria (R80.9: control) evaluation (R80.9)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Proteinuria Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | R80.9 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Chronic Kidney Disease & Electrolytes | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Serum Potassium, Bicarbonate in Proteinuria (R80.9: & Phosphorus) | K+ 3.8–4.8 mEq/L; HCO3 23–29 mEq/L (R80.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: eGFR (Creatinine + in Proteinuria (R80.9: Cystatin C)) | >= 90 mL/min/1.73m2 (R80.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Urine Albumin-to-Creatinine Ratio in Proteinuria (R80.9: (uACR)) | < 15 mg/g (< 30 mg/g normal) (R80.9) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Proteinuria
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Sibeprenlimab Voyxact • RxCUI 2728400 | FDA Prescription Therapeutic Agent | 74% | $1.0800 | $ 52.24 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Proteinuria)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Rosuvastatin and atorvastatin on kidney function:: What a 24,278-Participant Study Found Both RSV and ATV improve GFR, and ATV seems to be more effective in reducing proteinuria. Circulation journal : official journal of the Japanese Circulation Society • 2012-01-15 • Meta-Analysis | N = 24,278 | 99/100 | PMID 22382383 ↗ |
| New Insights on Atorvastatin and rosuvastatin on kidney: What a 29,147-Participant Study Found A and R show similar reno-protective effects in patients at high heart and blood vessel risk, with comparable rates of new onset proteinuria when commonly used doses are considered. International journal of cardiology • 2013-09-10 • Meta-Analysis | N = 29,147 | 99/100 | PMID 22633671 ↗ |
| New Insights on A clinical trial in type 2 diabetic: What a 1,715-Participant Study Found This large-scale international trial should help define the clinical course and standards of care for hypertensive adults with type 2. American journal of kidney diseases : the official journal of the National Kidney Foundation • 2001-10-15 • Randomized Controlled Trial | N = 1,715 | 96/100 | PMID 11576953 ↗ |
| New Insights on Kidney effects of atorvastatin and rosuvastatin in patients with diabetes who: What a 353-Participant Study Found Despite high-dose rosuvastatin lowering plasma lipid concentrations to a greater extent than did high-dose atorvastatin, atorvastatin seems to have more renoprotective effects for the studied chronic kidney disease population. The lancet. Diabetes & endocrinology • 2015-03-15 • Randomized Controlled Trial | N = 353 | 93/100 | PMID 25660356 ↗ |
| New Insights on Telmisartan is more effective than losartan in reducing proteinuria in patients: What a 860-Participant Study Found Mean systolic blood pressure reductions were not significantly different between groups at trial end. Kidney international • 2008-08-15 • Randomized Controlled Trial | N = 860 | 93/100 | PMID 18496508 ↗ |
Proteinuria Patient Community & “People Like Me” Threads
Filter Proteinuria community threads and patient logs by age, biological sex, dosage, and treatment duration.